Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature.

Singhal U, Wang Y, Henderson J, Niknafs YS, Qiao Y, Gursky A, Zaslavsky A, Chung JS, Smith DC, Karnes RJ, Chang SL, Feng FY, Palapattu GS, Taichman RS, Chinnaiyan AM, Tomlins SA, Morgan TM.

Mol Cancer Res. 2018 Apr;16(4):643-654. doi: 10.1158/1541-7786.MCR-17-0539. Epub 2018 Feb 16.

PMID:
29453313
2.

Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator.

Ankerst DP, Goros M, Tomlins SA, Patil D, Feng Z, Wei JT, Sanda MG, Gelfond J, Thompson IM, Leach RJ, Liss MA.

Eur Urol Focus. 2018 Feb 5. pii: S2405-4569(18)30011-7. doi: 10.1016/j.euf.2018.01.010. [Epub ahead of print]

PMID:
29422418
3.

Detailed pathologic analysis on the co-occurrence of non-seminomatous germ cell tumor subtypes in matched orchiectomy and retroperitoneal lymph node dissections.

Spratt DE, Suresh K, Osawa T, Schipper M, Jackson WC, Abugharib A, Lebastchi A, Smith D, Montgomery JS, Palapattu GS, Priya Kunju L, Wu A, Lew M, Tomlins SA, Chinnaiyan AM, Weizer AZ, Hafez KS, Kaffenberger SD, Udager A, Mehra R.

Med Oncol. 2018 Jan 31;35(3):21. doi: 10.1007/s12032-018-1090-y.

PMID:
29387987
4.

Molecular Biomarkers in the Clinical Management of Prostate Cancer.

Udager AM, Tomlins SA.

Cold Spring Harb Perspect Med. 2018 Jan 8. pii: a030601. doi: 10.1101/cshperspect.a030601. [Epub ahead of print]

PMID:
29311125
5.

Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma.

Ohe C, Smith SC, Sirohi D, Divatia M, de Peralta-Venturina M, Paner GP, Agaimy A, Amin MB, Argani P, Chen YB, Cheng L, Colecchia M, Compérat E, Werneck da Cunha I, Epstein JI, Gill AJ, Hes O, Hirsch MS, Jochum W, Kunju LP, Maclean F, Magi-Galluzzi C, McKenney JK, Mehra R, Nesi G, Osunkoya AO, Picken MM, Rao P, Reuter VE, de Oliveira Salles PG, Schultz L, Tickoo SK, Tomlins SA, Trpkov K, Amin MB.

Am J Surg Pathol. 2018 Mar;42(3):279-292. doi: 10.1097/PAS.0000000000001000.

PMID:
29309300
6.

Aldosterone-Producing Cell Clusters Frequently Harbor Somatic Mutations and Accumulate With Age in Normal Adrenals.

Omata K, Anand SK, Hovelson DH, Liu CJ, Yamazaki Y, Nakamura Y, Ito S, Satoh F, Sasano H, Rainey WE, Tomlins SA.

J Endocr Soc. 2017 May 12;1(7):787-799. doi: 10.1210/js.2017-00134. eCollection 2017 Jul 1.

7.

Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.

Hussain M, Daignault-Newton S, Twardowski PW, Albany C, Stein MN, Kunju LP, Siddiqui J, Wu YM, Robinson D, Lonigro RJ, Cao X, Tomlins SA, Mehra R, Cooney KA, Montgomery B, Antonarakis ES, Shevrin DH, Corn PG, Whang YE, Smith DC, Caram MV, Knudsen KE, Stadler WM, Feng FY, Chinnaiyan AM.

J Clin Oncol. 2018 Apr 1;36(10):991-999. doi: 10.1200/JCO.2017.75.7310. Epub 2017 Dec 20.

PMID:
29261439
8.

The CARMA3-Bcl10-MALT1 Signalosome Drives NFκB Activation and Promotes Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer.

Ekambaram P, Lee JL, Hubel NE, Hu D, Yerneni S, Campbell PG, Pollock N, Klei LR, Concel VJ, Delekta PC, Chinnaiyan AM, Tomlins SA, Rhodes DR, Priedigkeit N, Lee AV, Oesterreich S, McAllister-Lucas LM, Lucas PC.

Cancer Res. 2018 Mar 1;78(5):1225-1240. doi: 10.1158/0008-5472.CAN-17-1089. Epub 2017 Dec 19.

PMID:
29259013
9.

Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG.

J Clin Oncol. 2018 Feb 1;36(4):414-424. doi: 10.1200/JCO.2017.74.1173. Epub 2017 Dec 13.

PMID:
29236593
10.

Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms.

Paoletti C, Cani AK, Larios JM, Hovelson DH, Aung K, Darga EP, Cannell EM, Baratta PJ, Liu CJ, Chu D, Yazdani M, Blevins AR, Sero V, Tokudome N, Thomas DG, Gersch C, Schott AF, Wu YM, Lonigro R, Robinson DR, Chinnaiyan AM, Bischoff FZ, Johnson MD, Park BH, Hayes DF, Rae JM, Tomlins SA.

Cancer Res. 2018 Feb 15;78(4):1110-1122. doi: 10.1158/0008-5472.CAN-17-2686. Epub 2017 Dec 12.

PMID:
29233927
11.

Aldosterone-Producing Cell Clusters in Normal and Pathological States.

Omata K, Tomlins SA, Rainey WE.

Horm Metab Res. 2017 Dec;49(12):951-956. doi: 10.1055/s-0043-122394. Epub 2017 Dec 4.

PMID:
29202494
12.

Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy.

Hovelson DH, Liu CJ, Wang Y, Kang Q, Henderson J, Gursky A, Brockman S, Ramnath N, Krauss JC, Talpaz M, Kandarpa M, Chugh R, Tuck M, Herman K, Grasso CS, Quist MJ, Feng FY, Haakenson C, Langmore J, Kamberov E, Tesmer T, Husain H, Lonigro RJ, Robinson D, Smith DC, Alva AS, Hussain MH, Chinnaiyan AM, Tewari M, Mills RE, Morgan TM, Tomlins SA.

Oncotarget. 2017 Sep 22;8(52):89848-89866. doi: 10.18632/oncotarget.21163. eCollection 2017 Oct 27.

13.

Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays.

Skala SL, Xiao H, Udager AM, Dhanasekaran SM, Shukla S, Zhang Y, Landau C, Shao L, Roulston D, Wang L, Siddiqui J, Cao X, Magi-Galluzzi C, Zhang M, Osunkoya AO, Smith SC, McKenney JK, Betz BL, Myers JL, Chinnaiyan AM, Tomlins SA, Mehra R.

Mod Pathol. 2018 Jan;31(1):179-197. doi: 10.1038/modpathol.2017.99. Epub 2017 Aug 25.

PMID:
28840857
14.

Integrative clinical genomics of metastatic cancer.

Robinson DR, Wu YM, Lonigro RJ, Vats P, Cobain E, Everett J, Cao X, Rabban E, Kumar-Sinha C, Raymond V, Schuetze S, Alva A, Siddiqui J, Chugh R, Worden F, Zalupski MM, Innis J, Mody RJ, Tomlins SA, Lucas D, Baker LH, Ramnath N, Schott AF, Hayes DF, Vijai J, Offit K, Stoffel EM, Roberts JS, Smith DC, Kunju LP, Talpaz M, Cieślik M, Chinnaiyan AM.

Nature. 2017 Aug 17;548(7667):297-303. doi: 10.1038/nature23306. Epub 2017 Aug 2.

PMID:
28783718
15.

Comprehensive Molecular Profiling of Olfactory Neuroblastoma Identifies Potentially Targetable FGFR3 Amplifications.

Lazo de la Vega L, McHugh JB, Cani AK, Kunder K, Walocko FM, Liu CJ, Hovelson DH, Robinson D, Chinnaiyan AM, Tomlins SA, Harms PW.

Mol Cancer Res. 2017 Nov;15(11):1551-1557. doi: 10.1158/1541-7786.MCR-17-0135. Epub 2017 Aug 3.

PMID:
28775129
16.

Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.

Sanda MG, Feng Z, Howard DH, Tomlins SA, Sokoll LJ, Chan DW, Regan MM, Groskopf J, Chipman J, Patil DH, Salami SS, Scherr DS, Kagan J, Srivastava S, Thompson IM Jr, Siddiqui J, Fan J, Joon AY, Bantis LE, Rubin MA, Chinnayian AM, Wei JT; and the EDRN-PCA3 Study Group, Bidair M, Kibel A, Lin DW, Lotan Y, Partin A, Taneja S.

JAMA Oncol. 2017 Aug 1;3(8):1085-1093. doi: 10.1001/jamaoncol.2017.0177.

PMID:
28520829
17.

Fibulin-3 promotes muscle-invasive bladder cancer.

Han AL, Veeneman BA, El-Sawy L, Day KC, Day ML, Tomlins SA, Keller ET.

Oncogene. 2017 Sep 14;36(37):5243-5251. doi: 10.1038/onc.2017.149. Epub 2017 May 15.

PMID:
28504717
18.

Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy.

Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M, Speers C, Cooperberg MR, Kim W, Ryan CJ, Den RB, Freedland SJ, Posadas E, Sandler H, Klein EA, Black P, Seiler R, Tomlins SA, Chinnaiyan AM, Jenkins RB, Davicioni E, Ross AE, Schaeffer EM, Nguyen PL, Carroll PR, Karnes RJ, Spratt DE, Feng FY.

JAMA Oncol. 2017 Dec 1;3(12):1663-1672. doi: 10.1001/jamaoncol.2017.0751.

19.

Minimally Invasive Inguinal Lymphadenectomy in the Management of Penile Carcinoma.

Russell CM, Salami SS, Niemann A, Weizer AZ, Tomlins SA, Morgan TM, Montgomery JS.

Urology. 2017 Aug;106:113-118. doi: 10.1016/j.urology.2017.04.022. Epub 2017 Apr 24.

PMID:
28450202
20.

Molecular Profiling of Multiple Primary Merkel Cell Carcinoma to Distinguish Genetically Distinct Tumors From Clonally Related Metastases.

Harms KL, Lazo de la Vega L, Hovelson DH, Rahrig S, Cani AK, Liu CJ, Fullen DR, Wang M, Andea AA, Bichakjian CK, Johnson TM, Tomlins SA, Harms PW.

JAMA Dermatol. 2017 Jun 1;153(6):505-512. doi: 10.1001/jamadermatol.2017.0507.

PMID:
28403382
21.

Histopathological Classification of Cross-Sectional Image-Negative Hyperaldosteronism.

Yamazaki Y, Nakamura Y, Omata K, Ise K, Tezuka Y, Ono Y, Morimoto R, Nozawa Y, Gomez-Sanchez CE, Tomlins SA, Rainey WE, Ito S, Satoh F, Sasano H.

J Clin Endocrinol Metab. 2017 Apr 1;102(4):1182-1192. doi: 10.1210/jc.2016-2986.

22.

Genetic and Histopathologic Intertumor Heterogeneity in Primary Aldosteronism.

Omata K, Yamazaki Y, Nakamura Y, Anand SK, Barletta JA, Sasano H, Rainey WE, Tomlins SA, Vaidya A.

J Clin Endocrinol Metab. 2017 Jun 1;102(6):1792-1796. doi: 10.1210/jc.2016-4007.

PMID:
28368480
23.

Two-Stage Biomarker Protocols for Improving the Precision of Early Detection of Prostate Cancer.

Barnett CL, Tomlins SA, Underwood DJ, Wei JT, Morgan TM, Montie JE, Denton BT.

Med Decis Making. 2017 Oct;37(7):815-826. doi: 10.1177/0272989X17696996. Epub 2017 Mar 31.

PMID:
28363265
24.

Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay.

Torres A, Alshalalfa M, Tomlins SA, Erho N, Gibb EA, Chelliserry J, Lim L, Lam LLC, Faraj SF, Bezerra SM, Davicioni E, Yousefi K, Ross AE, Netto GJ, Schaeffer EM, Lotan TL.

J Mol Diagn. 2017 May;19(3):475-484. doi: 10.1016/j.jmoldx.2017.01.007. Epub 2017 Mar 21.

25.

A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma.

Smith SC, Sirohi D, Ohe C, McHugh JB, Hornick JL, Kalariya J, Karia S, Snape K, Hodgson SV, Cani AK, Hovelson D, Luthringer DJ, Martignoni G, Chen YB, Tomlins SA, Mehra R, Amin MB.

Histopathology. 2017 Jul;71(1):42-52. doi: 10.1111/his.13183. Epub 2017 Apr 12.

PMID:
28165631
26.

Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study.

Jackson WC, Desai NB, Abugharib AE, Tumati V, Dess RT, Lee JY, Zhao SG, Soliman M, Folkert M, Laine A, Hannan R, Zumsteg ZS, Sandler H, Hamstra DA, Montgomery JS, Miller DC, Kozminski MA, Hollenbeck BK, Hearn JW, Palapattu G, Tomlins SA, Mehra R, Morgan TM, Feng FY, Spratt DE.

BJU Int. 2017 Sep;120(3):351-357. doi: 10.1111/bju.13792. Epub 2017 Feb 26.

PMID:
28139024
27.

Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer.

Palapattu GS, Salami SS, Cani AK, Hovelson DH, Lazo de la Vega L, Vandenberg KR, Bratley JV, Liu CJ, Kunju LP, Montgomery JS, Morgan TM, Natarajan S, Huang J, Tomlins SA, Marks LS.

Clin Cancer Res. 2017 Feb 15;23(4):985-991. doi: 10.1158/1078-0432.CCR-16-1454. Epub 2016 Oct 7.

28.

Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.

Cani AK, Hovelson DH, Demirci H, Johnson MW, Tomlins SA, Rao RC.

Oncotarget. 2017 Jan 31;8(5):7989-7998. doi: 10.18632/oncotarget.14008.

29.

Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci: A Frequent Morphologic Pattern of Fumarate Hydratase-deficient Renal Cell Carcinoma.

Smith SC, Trpkov K, Chen YB, Mehra R, Sirohi D, Ohe C, Cani AK, Hovelson DH, Omata K, McHugh JB, Jochum W, Colecchia M, Amin M, Divatia MK, Hes O, Menon S, Werneck da Cunha I, Tripodi S, Brimo F, Gill AJ, Osunkoya AO, Magi-Galluzzi C, Sibony M, Williamson SR, Nesi G, Picken MM, Maclean F, Agaimy A, Cheng L, Epstein JI, Reuter VE, Tickoo SK, Tomlins SA, Amin MB.

Am J Surg Pathol. 2016 Nov;40(11):1457-1472.

30.

Independent surgical validation of the new prostate cancer grade-grouping system.

Spratt DE, Cole AI, Palapattu GS, Weizer AZ, Jackson WC, Montgomery JS, Dess RT, Zhao SG, Lee JY, Wu A, Kunju LP, Talmich E, Miller DC, Hollenbeck BK, Tomlins SA, Feng FY, Mehra R, Morgan TM.

BJU Int. 2016 Nov;118(5):763-769. doi: 10.1111/bju.13488. Epub 2016 Apr 19.

31.

The Role of Next-Generation Sequencing in Castration-Resistant Prostate Cancer Treatment.

Hovelson DH, Tomlins SA.

Cancer J. 2016 Sep/Oct;22(5):357-361. Review.

32.

Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis.

Zhao SG, Chang SL, Spratt DE, Erho N, Yu M, Ashab HA, Alshalalfa M, Speers C, Tomlins SA, Davicioni E, Dicker AP, Carroll PR, Cooperberg MR, Freedland SJ, Karnes RJ, Ross AE, Schaeffer EM, Den RB, Nguyen PL, Feng FY.

Lancet Oncol. 2016 Nov;17(11):1612-1620. doi: 10.1016/S1470-2045(16)30491-0. Epub 2016 Oct 12.

PMID:
27743920
33.

Prostatic Adenocarcinoma With Hormone Exposure Related Changes in a Patient With Hepatic Cirrhosis - Value of Autopsy in a Case Report.

Skala SL, Owens SR, Xiao H, Bauman KA, Tomlins SA, Chinnaiyan AM, Shao L, Jentzen JM, Gordon D, Mehra R.

Urol Case Rep. 2016 Sep 23;9:37-40. doi: 10.1016/j.eucr.2016.08.004. eCollection 2016 Nov.

34.

Targeted next-generation sequencing of CIC-DUX4 soft tissue sarcomas demonstrates low mutational burden and recurrent chromosome 1p loss.

Lazo de la Vega L, Hovelson DH, Cani AK, Liu CJ, McHugh JB, Lucas DR, Thomas DG, Patel RM, Tomlins SA.

Hum Pathol. 2016 Dec;58:161-170. doi: 10.1016/j.humpath.2016.09.004. Epub 2016 Sep 21.

35.

The ubiquitin ligase TRIM25 targets ERG for degradation in prostate cancer.

Wang S, Kollipara RK, Humphries CG, Ma SH, Hutchinson R, Li R, Siddiqui J, Tomlins SA, Raj GV, Kittler R.

Oncotarget. 2016 Oct 4;7(40):64921-64931. doi: 10.18632/oncotarget.11915.

36.

Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.

McDaniel AS, Ferraldeschi R, Krupa R, Landers M, Graf R, Louw J, Jendrisak A, Bales N, Marrinucci D, Zafeiriou Z, Flohr P, Sideris S, Crespo M, Figueiredo I, Mateo J, de Bono JS, Dittamore R, Tomlins SA, Attard G.

BJU Int. 2017 Nov;120(5B):E30-E44. doi: 10.1111/bju.13631. Epub 2016 Sep 18.

PMID:
27539393
37.

Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy.

Tosoian JJ, Almutairi F, Morais CL, Glavaris S, Hicks J, Sundi D, Humphreys E, Han M, De Marzo AM, Ross AE, Tomlins SA, Schaeffer EM, Trock BJ, Lotan TL.

Eur Urol. 2017 May;71(5):697-700. doi: 10.1016/j.eururo.2016.07.026. Epub 2016 Jul 28.

38.

Translational and clinical implications of the genetic landscape of prostate cancer.

Spratt DE, Zumsteg ZS, Feng FY, Tomlins SA.

Nat Rev Clin Oncol. 2016 Oct;13(10):597-610. doi: 10.1038/nrclinonc.2016.76. Epub 2016 Jun 1. Review.

39.

Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches.

Udager AM, Liu TY, Skala SL, Magers MJ, McDaniel AS, Spratt DE, Feng FY, Siddiqui J, Cao X, Fields KL, Morgan TM, Palapattu GS, Weizer AZ, Chinnaiyan AM, Alva A, Montgomery JS, Tomlins SA, Jiang H, Mehra R.

Ann Oncol. 2016 Sep;27(9):1706-12. doi: 10.1093/annonc/mdw216. Epub 2016 May 23.

40.

Independent validation of the prognostic capacity of the ISUP prostate cancer grade grouping system for radiation treated patients with long-term follow-up.

Spratt DE, Jackson WC, Abugharib A, Tomlins SA, Dess RT, Soni PD, Lee JY, Zhao SG, Cole AI, Zumsteg ZS, Sandler H, Hamstra D, Hearn JW, Palapattu G, Mehra R, Morgan TM, Feng FY.

Prostate Cancer Prostatic Dis. 2016 Sep;19(3):292-7. doi: 10.1038/pcan.2016.18. Epub 2016 May 24.

PMID:
27215611
41.

Double adrenocortical adenomas harboring independent KCNJ5 and PRKACA somatic mutations.

Nanba K, Omata K, Tomlins SA, Giordano TJ, Hammer GD, Rainey WE, Else T.

Eur J Endocrinol. 2016 Aug;175(2):K1-6. doi: 10.1530/EJE-16-0262. Epub 2016 May 10.

42.

Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies.

Cani AK, Soliman M, Hovelson DH, Liu CJ, McDaniel AS, Haller MJ, Bratley JV, Rahrig SE, Li Q, Briceño CA, Tomlins SA, Rao RC.

Mod Pathol. 2016 Jul;29(7):685-97. doi: 10.1038/modpathol.2016.79. Epub 2016 Apr 22.

43.

Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations.

Harms PW, Hovelson DH, Cani AK, Omata K, Haller MJ, Wang ML, Arps D, Patel RM, Fullen DR, Wang M, Siddiqui J, Andea A, Tomlins SA.

Hum Pathol. 2016 May;51:25-31. doi: 10.1016/j.humpath.2015.12.015. Epub 2016 Jan 7.

PMID:
27067779
44.

Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence.

Cole AI, Morgan TM, Spratt DE, Palapattu GS, He C, Tomlins SA, Weizer AZ, Feng FY, Wu A, Siddiqui J, Chinnaiyan AM, Montgomery JS, Kunju LP, Miller DC, Hollenbeck BK, Wei JT, Mehra R.

J Urol. 2016 Aug;196(2):405-11. doi: 10.1016/j.juro.2016.01.120. Epub 2016 Feb 23.

PMID:
26920466
45.

Prostate cancer characterization by optical contrast enhanced photoacoustics.

Xu G, Qin M, Mukundan A, Siddiqui J, Takada M, Vilar-Saavedra P, Tomlins SA, Kopelman R, Wang X.

Proc SPIE Int Soc Opt Eng. 2016 Feb 13;9708. pii: 97080I. doi: 10.1117/12.2213064. Epub 2016 Mar 15.

46.

Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.

Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BV, Varambally S, Tomlins SA, Nanus DM, Tagawa ST, Van Allen EM, Elemento O, Sboner A, Garraway LA, Rubin MA, Demichelis F.

Nat Med. 2016 Mar;22(3):298-305. doi: 10.1038/nm.4045. Epub 2016 Feb 8.

47.

Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing.

Tillman BN, Yanik M, Birkeland AC, Liu CJ, Hovelson DH, Cani AK, Palanisamy N, Carskadon S, Carey TE, Bradford CR, Tomlins SA, McHugh JB, Spector ME, Brenner JCh.

Head Neck. 2016 Apr;38 Suppl 1:E1646-52. doi: 10.1002/hed.24292. Epub 2016 Feb 5.

48.

Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer.

Qiao Y, Feng FY, Wang Y, Cao X, Han S, Wilder-Romans K, Navone NM, Logothetis C, Taichman RS, Keller ET, Palapattu GS, Alva AS, Smith DC, Tomlins SA, Chinnaiyan AM, Morgan TM.

Neoplasia. 2016 Jan;18(1):1-9. doi: 10.1016/j.neo.2015.11.009.

49.

Molecular Heterogeneity in Aldosterone-Producing Adenomas.

Nanba K, Chen AX, Omata K, Vinco M, Giordano TJ, Else T, Hammer GD, Tomlins SA, Rainey WE.

J Clin Endocrinol Metab. 2016 Mar;101(3):999-1007. doi: 10.1210/jc.2015-3239. Epub 2016 Jan 14.

50.

Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.

Evans JR, Zhao SG, Chang SL, Tomlins SA, Erho N, Sboner A, Schiewer MJ, Spratt DE, Kothari V, Klein EA, Den RB, Dicker AP, Karnes RJ, Yu X, Nguyen PL, Rubin MA, de Bono J, Knudsen KE, Davicioni E, Feng FY.

JAMA Oncol. 2016 Apr;2(4):471-80. doi: 10.1001/jamaoncol.2015.4955.

Supplemental Content

Loading ...
Support Center